Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High After Analyst Upgrade

Posted by George Bondi on Jun 29th, 2026

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) reached a new 52-week high during mid-day trading on Monday after JonesTrading raised their price target on the stock from $45.00 to $70.00. JonesTrading currently has a buy rating on the stock. Enliven Therapeutics traded as high as $50.97 and last traded at $50.0140, with a volume of 54786 shares. The stock had previously closed at $50.08.

ELVN has been the subject of several other reports. HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Mizuho lifted their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. The Goldman Sachs Group raised their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $64.50.

View Our Latest Report on ELVN

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at $2,233,800. The trade was a 10.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP boosted its stake in Enliven Therapeutics by 159.4% in the first quarter. Seven Fleet Capital Management LP now owns 259,283 shares of the company’s stock valued at $10,164,000 after acquiring an additional 159,330 shares during the period. DV Trading LLC bought a new position in shares of Enliven Therapeutics during the first quarter valued at approximately $3,734,000. Avidity Partners Management LP raised its position in shares of Enliven Therapeutics by 185.1% during the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock worth $15,680,000 after purchasing an additional 259,700 shares during the period. Bank of America Corp DE raised its position in shares of Enliven Therapeutics by 38.1% during the 1st quarter. Bank of America Corp DE now owns 45,162 shares of the company’s stock worth $1,770,000 after purchasing an additional 12,451 shares during the period. Finally, Stempoint Capital LP bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth approximately $14,247,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

The firm has a market cap of $3.06 billion, a P/E ratio of -30.17 and a beta of 0.29. The firm has a fifty day moving average of $42.17 and a 200-day moving average of $32.55.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current year.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.